myFibroScan2.5.0 - App Store

FibroScan(R) is the non-invasive gold standard solution for comprehensive management of liver health.

FibroScan(R) is powered by three unique, patented and validated biomarkers, LSM by VCTE(TM) (Liver Stiffness Measurement) and CAP(TM) (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines.

myFibroScan app is your everyday FibroScan(R) companion to access Interpretation Guide and FibroScan(R) based scores in an easy, fast and intuitive way :

The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan(R) examination results.

Scores enhance FibroScan(R) liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.

. Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast.
. Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE(TM) and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
. Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE(TM) and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.

MASH Treatment Eligibility Tool to eliminate the Guesswork.
This patient management tool embeds treatment recommendations based on the patient’s FibroScan(R) results and the latest AASLD Guidance.

Version History myFibroScan, your Everyday FibroScan® Companion, evolves to bring you:
• Updated Clinical References: The Interpretation Guide now includes the most recent publications, ensuring the tool reflects the latest clinical knowledge.
• New MASH Treatment Eligibility Tool (USA only): Take the guesswork out of patient management. This new feature integrates treatment recommendations based on FibroScan® results and the latest AASLD Guidance.
• Translated in Italian in addition to the existing English, French and German version 2.5.0 11/04/2025 Technological update with new development framework 2.4.0 04/19/2024 myFibroScan is now available in Spanish 2.3.0 05/19/2022 Fix an issue to enter decimal value 2.2.2 11/23/2021 Introduction of novel FibroScan based scores: Agile™ 3+ and Agile™ 4 for the identification of advanced fibrosis and cirrhosis in patients suspected of NAFLD. 2.2.1 06/17/2021 Compliancy with latest Pubmed constraints and iOS 13 requirements 2.1.1 09/24/2020 Introduction of FAST™ score, highly scalable score for at-risk NASH patients identification combining FibroScan® biomarkers of liver fibrosis (VCTE™) and steatosis (CAP™) with blood biomarker of liver inflammation (AST) 2.1.0 02/06/2020 Introduction of FAST™ score, highly scalable score for at-risk NASH patients identification combining FibroScan® biomarkers of liver fibrosis (VCTE™) and steatosis (CAP™) with blood biomarker of liver inflammation (AST). 2.0.1 11/07/2019 New feature EASL 2018 - Interpretation Guides: According to scientific publications, assist all FibroScan users in interpreting patient examinations results (Fibrosis stage and Steatosis grade) 1.3.9 04/03/2018 Minor bug corrections 1.2.1 04/19/2017 1.2.0 04/16/2017